CMA issues Concordia statement of objections
The UK’s Competition and Markets Authority has accused pharmaceutical company Concordia of overcharging the National Health Service and hiking the price of an essential drug by 6,000%.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.